Beam Therapeutics (BEAM) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Beam Therapeutics (NASDAQ: BEAM) in the last few weeks:

• 3/12/2025 – Beam Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 3/10/2025 – Beam Therapeutics was upgraded by analysts at Scotiabank from a “sector perform” rating to a “sector outperform” rating. They now have a $40.00 price target on the stock.
• 3/10/2025 – Beam Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
• 3/10/2025 – Beam Therapeutics was upgraded by analysts at Jones Trading from a “hold” rating to a “buy” rating. They now have a $34.00 price target on the stock.
• 3/10/2025 – Beam Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
• 3/3/2025 – Beam Therapeutics had its price target raised by analysts at Scotiabank from $24.00 to $25.00. They now have a “sector perform” rating on the stock.
• 2/28/2025 – Beam Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
• 2/27/2025 – Beam Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $78.00 price target on the stock.
• 2/26/2025 – Beam Therapeutics had its price target raised by analysts at Royal Bank of Canada from $24.00 to $26.00. They now have a “sector perform” rating on the stock.
• 2/3/2025 – Beam Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
• 1/29/2025 – Beam Therapeutics was upgraded by analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating.

Beam Therapeutics Trading Down 7.9 %

NASDAQ BEAM traded down $1.93 during trading hours on Tuesday, reaching $22.59. 1,922,684 shares of the company’s stock were exchanged, compared to its average volume of 1,206,566. The stock has a market cap of $2.25 billion, a PE ratio of -12.84 and a beta of 1.91. Beam Therapeutics Inc. has a one year low of $20.84 and a one year high of $36.75. The firm has a fifty day moving average of $27.05 and a 200-day moving average of $26.00.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.16. The business had revenue of $30.00 million for the quarter, compared to analyst estimates of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. Beam Therapeutics’s revenue for the quarter was down 90.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.73 EPS. As a group, research analysts forecast that Beam Therapeutics Inc. will post -4.57 EPS for the current year.

Insiders Place Their Bets

In other news, CEO John M. Evans sold 30,000 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the transaction, the chief executive officer now owns 908,659 shares of the company’s stock, valued at $24,306,628.25. This represents a 3.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the transaction, the insider now directly owns 102,968 shares in the company, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Beam Therapeutics in the 4th quarter valued at $330,000. Charles Schwab Investment Management Inc. increased its position in shares of Beam Therapeutics by 6.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 629,492 shares of the company’s stock valued at $15,423,000 after buying an additional 36,226 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Beam Therapeutics by 11.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock valued at $98,149,000 after buying an additional 404,782 shares in the last quarter. Bellevue Group AG increased its position in shares of Beam Therapeutics by 7.1% in the 3rd quarter. Bellevue Group AG now owns 1,518,121 shares of the company’s stock valued at $37,194,000 after buying an additional 100,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Beam Therapeutics by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company’s stock worth $44,297,000 after purchasing an additional 78,102 shares in the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.